-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Colorectal cancer (CRC) is one of the most common malignant tumors in the world
.
The annual incidence of CRC is estimated to exceed 1.
Colorectal cancer (CRC) is one of the most common malignant tumors in the world
Recently, a research institution has identified a previously unknown protein and performed its functional characterization.
Because of its abundant content in astrocytes, they called it ASTROPRINCIN (APCN)
.
APCN, also annotated as FAM171A1, is present in the trophoblast cells of the early placenta
The researchers used immunohistochemistry to perform tissue microarray analysis in the tumors of 429 CRC patients in the clinical follow-up period and 255 CRC patients in the verification cohort
.
The results of the study found that low or missing APCN expression is associated with a good prognosis of CRC patients, and high APCN expression is a sign of poor prognosis in cancer patients
.
Cox univariate and multivariate analysis showed that elevated APCN tumor expression is a powerful sign of poor prognosis, and has nothing to do with stage, grade, patient age or gender
Figure: APCN immunohistochemistry results
The results of this study indicate that APCN is a new independent prognostic marker in CRC, and patients with high APCN expression may require more active postoperative adjuvant treatment and follow-up
.
.
Original source:
Tuomas Kaprio.
Elevated tumor expression of Astroprincin (FAM171A1) is an independent marker of poor prognosis in colon cancer.
Leave a message here
